The goal is to establish a robust assay format with clinically relevant sensitivity and specificity, the company states. A successful outcome would provide the basis for a commercially attractive diagnostic test with considerably shorter time to market than traditional drug development, it states further.

Related article

Global health & Local efforts: New hope in the neurodegenerative disease pipeline 

Even though many have tried and few succeeded in the quest to find viable treatments for neurodegenerative diseases, Nordic drug developers continue to take different approaches to crack the riddle.

“The growing interest from global diagnostics companies confirms that our data on naturally occurring protective antibodies has strong commercial value. We are prioritising this opportunity as a key commercial pillar for Alzinova and, together with Amsterdam UMC, we are now taking a focused step to translate this biology into a scalable blood test that can be integrated into major diagnostic portfolios. Our goal is to create a new revenue stream for Alzinova in the near term and, over time, to position the test as a companion diagnostic to our therapeutic vaccine ALZ‑101, thereby creating a stronger platform for sustainable revenue generation and long‑term value creation for Alzinova,” says Tord Labuda, CEO of Alzinova.

The collaboration is expected to run for approximately 3 to 4 months, with initial results anticipated in the third quarter of 2026, and will be carried out within Alzinova’s existing budget. The work is independent of the ongoing clinical development of ALZ‑101 but has the potential to create significant long‑term synergies between diagnostics and therapy within the same disease‑modifying platform, the company states.